newsfilter
← Latest News
Business Wire·

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized to deliver on key milestones following